– Nzyme, a private equity fund backed by Kibo Ventures, has closed at €160 million.
– The fund will invest in profitable Spanish companies in highly fragmented B2B sectors, focusing on traditional businesses with strong transformation potential through technology adoption and sector consolidation.
– Nzyme applies a prudent, hands-on investment approach, targeting well-managed companies with solid structures and supporting their expansion efforts.
– The fund focuses on companies that have proven success in local markets, many located outside major urban centers, helping them scale, professionalize, and integrate technology.
– Nzyme supports businesses in transitioning from 20–40 employees to organizations of over 150, with scalable processes, integrated technology, and international ambitions.
– Target companies typically have EBITDA starting at €1 million or around 20 employees, serving as a foundation for sector platform-building.
– Nzyme plans to build 8 to 10 platform companies, making investments of €15 to €20 million each through acquisitions and integrations.
– The investment strategy combines inorganic growth with advanced technologies, including AI, big data, machine learning, IoT, edge computing, and cloud, to enhance efficiency, scalability, and competitive positioning.
– Initial investments include an entry into healthcare distribution integrated into Kuma Group and several acquisitions in professional services.
– In April 2025, Nzyme successfully exited Kuma’s dental division, less than two years after acquisition.
– The fund’s management team includes Fernando Díaz Solís, Vicente Vázquez Bouza, José Manuel Gasalla, Juan López Santamaría, and Pablo Campos, supported by the Kibo Ventures network.
– Oliver Wyman serves as Nzyme’s strategic advisor.
– Nzyme has attracted a diverse investor base, including CDTI Innovación – Centro para el Desarrollo Tecnológico y la Innovación through its SICC Innvierte, historic Spanish business families, successful entrepreneurs, banks, and international family offices.
– Vicente Vazquez Bouza, Managing Director at Nzyme, stated that the fund’s successful closing reflects strong investor confidence in the team, the strategy, and the growth potential of Spanish SMEs.
– Nzyme is committed to creating strong leaders in traditional sectors by combining consolidation and technological innovation, with a goal of generating sustainable value and contributing to Spain’s economic development.
